- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Top 5 AI Stories of 2023
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.
The Promise and Challenges of Generative AI in Healthcare
Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can create the greatest benefits.
Embracing AI: Q&A with Shalu Chadha
Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.
AI and Drug 'Re-Innovation'
The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.
Harnessing AI for Pharma Sales
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Data, AI, and the New Era of Field Teams: Q&A with Paul Shawah, executive vice president of commercial strategy at Veeva
Setting up a field team for the future necessitates equipping it with a toolbox of cutting-edge technological advancements. These tools enable the team to swiftly acquire essential, accurate information, as collectively advocated by biopharma organizations at Veeva's May 2023 Commercial Summit. Senior editor Fran Pollaro spoke with Paul Shawah, Veeva's executive vice president of commercial strategy, about the roles of data, ChatGPT, and AI in introducing new medicines to the market.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
